CAR-T

CAR-T therapy generally begins with leukapheresis to obtain autologous T cells; under experimental conditions, a chimeric antigen receptor is introduced via a vector, enabling them to recognize specific tumor antigens. After quality release, a short course of lymphodepletion therapy is usually given to facilitate cell expansion, followed by CAR-T reinfusion. During this period, vital signs, infection, and neurological status are continuously monitored, and symptomatic and supportive treatment is given as needed. The overall goal is to achieve cell expansion and assess disease response. The above is general health information, not medical advice; specific details are subject to specialist evaluation and hospital protocols.